Cenomed presents preclinical data on lead drugs

Cenomed BioSciences, a majority-owned subsidiary of USA-based Abraxis BioScience, presented strong data at the annual meeting of the Society for Neuroscience in Washington DC, USA, on two lead compounds with promise for the treatment of schizophrenia and post-traumatic stress disorder.

The potential anti-psychotic, CM-2,303, has a unique mechanism-of-action and yielded positive findings in preclinical models predicting effectiveness in the treatment of schizophrenia. The firm hopes to begin Phase I safety and efficacy testing during the second half of 2009.

The second compound discussed at the conference, CM-2,236, is under evaluation as a drug candidate for use in the prevention and/or treatment of PTSD.